Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry
Mckleroy W, Shing T, Anderson WH, et al. Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry. JAMA. 1 Aug 2023;330(5):442-453.
“The primary outcome was assessment for accelerated decline in lung function (FEV1) in participants with symptomatic TEPS vs asymptomatic TEPS (preserved spirometry). Secondary outcomes included development of COPD defined by spirometry, respiratory symptoms, rates of respiratory exacerbations, and progression of computed tomographic–defined airway wall thickening or emphysema.
https://jamanetwork.com/journals/jama/fullarticle/2807747
At a median follow-up of 5.76 years, the decline in FEV1 was −31.3 mL/y for participants with symptomatic TEPS vs −38.8 mL/y for those with asymptomatic TEPS (between-group difference, −7.5 mL/y [95% CI, −16.6 to 1.6 mL/y]). The cumulative incidence of COPD was 33.0% among participants with symptomatic TEPS vs. 31.6% among those with asymptomatic TEPS (hazard ratio, 1.05 [95% CI, 0.76 to 1.46]).”
Comment: Smokers who may not have been diagnosed with lung disease have significant respiratory effects from long-term use of tobacco as measured by spirometry.
Stephen Hamann
